Leerink Partners, the health-care advisory firm, has continued a recent recruitment drive with hires from boutiques ...
Leerink downgraded 908 Devices (MASS) to Market Perform from Outperform with a price target of $4, down from $12. Though the firm still sees ...
Bristol-Myers Squibb (BMY) stock was upgraded by Leerink Partners based on a potential sales boost for its schizophrenia ...
Fintel on MSN23h
Leerink Partners Downgrades 908 Devices (MASS)Fintel reports that on November 13, 2024, Leerink Partners downgraded their outlook for 908 Devices (NasdaqGM:MASS) from ...
As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...
Leerink Partners analyst Mani Foroohar maintained a Hold rating on CureVac (CVAC – Research Report) on November 12. The company’s ...
Celldex Therapeutics, Inc. (NASDAQ:CLDX – Free Report) – Leerink Partnrs cut their FY2024 EPS estimates for Celldex ...
Beam Therapeutics (BEAM) stock gains as Leerink upgrades the biotech despite a fatality in a gene editing study, citing an ...
Leerink Partners has recently resumed MannKind Corp (MNKD) stock to Outperform rating, as announced on September 9, 2024, according to Finviz. Earlier, on June 13, 2024, Rodman & Renshaw had initiated ...
Investment analysts at Leerink Partnrs lifted their FY2024 earnings per share (EPS) estimates for shares of Xencor in a ...
Leerink upgraded Beam Therapeutics (BEAM) to Outperform from Market Perform with a price target of $39, up from $27. The firm notes that prior to Tuesday’s BEAM-101 data in sickle-cell disease ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback